The current status and future applications of interleukin-2 and adoptive immunotherapy in cancer treatment
- 1 May 1988
- journal article
- clinical trial
- Published by Elsevier in Seminars in Oncology Nursing
- Vol. 4 (2) , 132-141
- https://doi.org/10.1016/0749-2081(88)90071-x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1987
- Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trialsJournal of Immunological Methods, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Monoclonal Antibody Imaging of Human MelanomaAnnals of Surgery, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.The Journal of Experimental Medicine, 1982
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975